rapcabtagene autoleucel

Phase 2Cell therapy

rapcabtagene autoleucel is one of 51 biologic programs targeting Idiopathic Inflammatory Myopathies. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Idiopathic Inflammatory MyopathiesActive, not recruiting

Large-Cell LymphomaNot yet recruiting

Lupus Erythematosus, SystemicActive, not recruiting

Rheumatoid Arthritis (RA)Active, not recruiting

ANCA Associated Vasculitis (AAV)Active, not recruiting

Progressive Multiple SclerosisActive, not recruiting

Scleroderma, DiffuseActive, not recruiting

Relapsing Multiple SclerosisActive, not recruiting

DLBCLActive, not recruiting

Idiopathic Inflammatory MyopathiesPhase 2

Active, not recruiting

Large-Cell LymphomaPhase 1

Not yet recruiting

Lupus Erythematosus, SystemicPhase 2

Active, not recruiting

Rheumatoid Arthritis (RA)Preclinical

Active, not recruiting

ANCA Associated Vasculitis (AAV)Phase 2

Active, not recruiting

Progressive Multiple SclerosisPreclinical

Active, not recruiting

Scleroderma, DiffusePhase 2

Active, not recruiting

Relapsing Multiple SclerosisPreclinical

Active, not recruiting

DLBCLPhase 2

Active, not recruiting

Competition

Competitive Landscape

21 competitors in DLBCL

#DrugCompanyPhaseTrials

Nolvadex

AstraZeneca

Phase 3

1 2

COLUMVI

Roche

Phase 2

3 3

Gemzar

Johnson & Johnson

Phase 2

2 4

Eloxatin

Teva

Phase 2

2 5

Epkinly

Genmab

Phase 2

2 6

Aliqopa

Bayer

Phase 2

1 7

Yescarta

Gilead

Phase 2

1 8

Venclexta

AbbVie

Phase 2

1 9

Gazyva

Roche

Phase 2

1 10

Imbruvica

PPharmacyclics LLC.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1/2Active, not recruiting

DLBCL

NCT03960840

Q3 2028

Phase 1Not yet recruiting

Large-Cell Lymphoma

NCT07443137

Q4 2028

PreclinicalActive, not recruiting

Rheumatoid Arthritis (RA)

NCT07048197

Q2 2030

Phase 2Active, not recruiting

ANCA Associated Vasculitis (AAV)

NCT06868290

PreclinicalActive, not recruiting

Progressive Multiple Sclerosis

NCT06675864

Clinical

Trials by Indication[1]

DLBCL1 trial

Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

Active, not recruiting· Novartis logo

Novartis·Phase 1/2·NCT03960840·217 enrolled

Progressive Multiple Sclerosis1 trial

An Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression, and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)

Active, not recruiting· Novartis logo

Novartis·Preclinical·NCT06675864·28 enrolled

ANCA Associated Vasculitis (AAV)1 trial

A Phase 2, Randomized, Open-label, Controlled Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Comparator in Participants With Severe Active Granulomatosis With Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)

Active, not recruiting· Novartis logo

Novartis·Phase 2·NCT06868290·126 enrolled

Rheumatoid Arthritis (RA)1 trial

An Open-label, Multi-center, Phase 1/2 Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Participants With Difficult-to-treat Rheumatoid Arthritis and Severe, Refractory Sjogren's Disease With Organ Involvement

Active, not recruiting· Novartis logo

Novartis·Preclinical·NCT07048197·27 enrolled

Lupus Erythematosus, Systemic1 trial

A Phase 2, Open-label, Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel in Patients With Active, Refractory Systemic Lupus Erythematosus (SLE) or Active, Refractory Lupus Nephritis (LN).

Active, not recruiting· Novartis logo

Novartis·Phase 2·NCT06581198·179 enrolled

4 more indications

Scleroderma, Diffuse1 trial

A Phase II, Multi-part, Randomized, Open-label, Assessor-blinded, Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Rituximab Treatment in Participants With Severe Refractory Diffuse Cutaneous Systemic Sclerosis

Active, not recruiting· Novartis logo

Novartis·Phase 2·NCT06655896·96 enrolled

Relapsing Multiple Sclerosis1 trial

An Open-label, Multi-center, Phase 1/2 Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Participants With Relapsing Multiple Sclerosis With Breakthrough Disease Activity During Previous Treatment With a Highly Efficacious Therapy

Active, not recruiting· Novartis logo

Novartis·Preclinical·NCT06617793·28 enrolled

Large-cell Lymphoma1 trial

Rapcabtagene Autoleucel for Eradication of Measurable Residual Disease in Large B-Cell Lymphoma (LBCL)

Not yet recruiting·SStanford University·Phase 1·NCT07443137·20 enrolled

Idiopathic Inflammatory Myopathies1 trial

A Phase 2, Randomized, Open-label, Controlled Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Comparator in Participants With Severe Refractory Idiopathic Inflammatory Myopathies (IIM)

Active, not recruiting· Novartis logo

Novartis·Phase 2·NCT06665256·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for rapcabtagene autoleucel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — rapcabtagene autoleucel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for rapcabtagene autoleucel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: Novartis

rapcabtagene autoleucel

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q3 2028

Q4 2028

Q2 2030

Trials by Indication[1]

DLBCL1 trial

Progressive Multiple Sclerosis1 trial

ANCA Associated Vasculitis (AAV)1 trial

Rheumatoid Arthritis (RA)1 trial

Lupus Erythematosus, Systemic1 trial

Scleroderma, Diffuse1 trial

Relapsing Multiple Sclerosis1 trial

Large-cell Lymphoma1 trial

Idiopathic Inflammatory Myopathies1 trial

References

Drug Info

Quick Facts

Related News